Intellia Therapeutics (NASDAQ:NTLA) CAO Sells 2,641 Shares of Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 2,641 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Intellia Therapeutics Stock Up 1.6%

NASDAQ NTLA traded up $0.28 on Monday, reaching $17.84. The company had a trading volume of 3,834,214 shares, compared to its average volume of 5,666,633. The stock has a market capitalization of $2.49 billion, a PE ratio of -5.04 and a beta of 1.77. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25. The firm’s 50 day moving average price is $14.13 and its 200 day moving average price is $13.07.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. During the same quarter last year, the business posted ($1.10) earnings per share. On average, research analysts expect that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NTLA shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 15th. Truist Financial raised shares of Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. The Goldman Sachs Group boosted their price target on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research report on Tuesday, April 28th. Chardan Capital upped their price target on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.46.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NTLA. Oppenheimer & Co. Inc. lifted its holdings in shares of Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after acquiring an additional 808 shares during the last quarter. Comerica Bank grew its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares during the period. Wealthfront Advisers LLC raised its position in Intellia Therapeutics by 7.6% in the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock worth $185,000 after purchasing an additional 1,018 shares during the period. Finally, Benjamin Edwards Inc. lifted its stake in Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after purchasing an additional 1,126 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.